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Renal tubular lysosomal enzyme activities like alanine aminopeptidase (AAP) and N-acetyl-𝛽-D-glucosaminidase (NAG) have
been shown to increase in patients developing diabetic nephropathy and nephrosclerosis. This study aimed to determine the
activities of N-acetyl-𝛽-D-glucosaminidase and alanine aminopeptidase and albumin concentration in urine samples of patients
with type 2 diabetes. One hundred and thirty (65 type 2 diabetic and 65 nondiabetic) subjects participated in this study. Blood
samples were drawn for measurements of fasting blood glucose, albumin (Alb), lipids, and creatinine (Cr). Early morning spot
urine samples were also collected for activities of alanine aminopeptidase (AAP), N-acetyl-𝛽-D-glucosaminidase (NAG), and
concentration of albumin (U-Alb) and creatinine (U-Cr). Both NAG/Cr and AAP/Cr were significantly increased in diabetic
subjects compared to controls (𝑝 < 0.001). There was positive correlation between NAG/Cr and Alb/Cr (𝑟 = 0.49, 𝑝 < 0.001)
and between NAG/Cr and serum creatinine (𝑟 = 0.441, 𝑝 < 0.001). A negative correlation was found between NAG/Cr and eGFR
(𝑟 = −0.432, 𝑝 < 0.05). 9.3% and 12% of diabetics with normoalbuminuria had elevated levels of AAP/Cr andNAG/Cr, respectively.
We conclude that measuring the urinary enzymes activities (NAG/Cr and AAP/Cr) could be useful as a biomarker of early renal
involvement in diabetic complications.
1. Introduction
Diabetic nephropathy (DN) and nephrosclerosis are clinical
conditions characterized by persistent albuminuria, arte-
rial blood pressure elevation, and an increasing decline in
glomerular filtration rate (GFR) [1–4]. Patients with the
above conditions represent major complications developed
in diabetes mellitus and have a higher risk of developing
cardiovascular diseases (CVD) [5–7].This imposes enormous
medical, economic, and social burden in terms of costs on
both the patient and the health care system. Early clinical
manifestation of diabetic nephropathy is the appearance of
microalbuminuria, defined by a urinary albumin excretion
rate of 30–300mg/24 hrs or 30–300mg/g of creatinine in a
spot urine sample, which predicts renal function deterio-
ration and poor outcome. Even though microalbuminuria
is the most widely used test of development of diabetic
nephropathy, it does not manifest clinically until stage 3 of
the five stages of development of diabetic nephropathy [8].
During the development of DN, certain lysosomal enzymes
are secreted into the urine. Lysosomal enzymatic activities
have been shown to be elevated in urine samples of patients
developing diabetic nephropathy earlier than appearance of
microalbuminuria [9]. N-acetyl-𝛽-D-glucosaminidase and
alanine aminopeptidase are among the renal tubular lysoso-
mal enzymes that have been shown to be excreted in higher
concentrations during the early development of diabetic
nephropathy. Early detection of renal involvement in DN,
through urinary activities of alanine aminopeptidase (AAP)
and N-acetyl-𝛽-D-glucosaminidase (NAG), can draw the
attention of clinicians to possible development of DN and
therefore put in place appropriate therapeutic measures in
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order to prevent the disease progressing to end stage, thereby
leading to increased survival and lower treatment cost. The
objective of this study was to determine the activities of
N-acetyl-𝛽-D-glucosaminidase and alanine aminopeptidase
and albumin concentration in urine samples of patients with
type 2 diabetes mellitus.
2. Materials and Methods
2.1. Study Site, Design, Participants, and Exclusion Criteria.
This was a hospital based cross-sectional study with matched
controls, carried out at the National Diabetes Management
andResearchCentre (NDMRC),Korle-buTeachingHospital,
Accra, Ghana, from October 2013 to July 2014. Subjects who
served as controls were screened to make sure that they
were nondiabetic. A total of 301 subjects were spoken to
and 223 agreed to participate in the study. Detailed medical
history and examination were conducted by a diabetologist
to exclude subjects with conditions that could affect results
outcome such as subjects with renal and liver diseases,
proteinuria, pregnancy, immunosuppression, and urinary
tract infections (UTI). Finally, 130 subjects comprising 65
type 2 diabetics and 65 healthy controls between the ages of
25 and 83 years were involved in the study. The University
of Ghana Medical School Ethical and Protocol review com-
mittee reviewed and approved the study. Informed written
consent was obtained from all participants in accordance
with the Helsinki Declaration [10]. A questionnaire covering
participants’ lifestyle, dietary habits, anthropometrics, and
medications used was administered to each participant that
consented. Anthropometric measurements such as height
and weight were taken and body mass index was calculated.
Blood pressurewas taken using amercury sphygmomanome-
ter and stethoscope after participants had rested for 15
minutes.
2.1.1.MinimumSample Size. Assuming odds ratio of 2 among
diabetic subjects for albuminuria, at a 5% significant level and
a power of 80%, a sample size of 60 persons was adequate for
this study.
2.1.2. Laboratory Procedure. This study used a morning spot
urine sample as recommended by Kidney Disease Outcomes
Quality Initiative (KDOQI). Early morning spot urine sam-
ples from study subjects were collected into sterile plastic
universal urine containers. Samples were centrifuged at
2000 g for 10minutes. Dipstick evaluation for proteinuria and
urine analysis was performed on each sample. Five milliliters
(5mL) of venous blood sample was collected between 6
am and 8 am, after participants had fasted for 10–14 hours.
Four milliliters (4mL) of the blood sample was transferred
into serum separator tubes and processed. The resulting sera
after processing were aliquoted into Eppendorf tubes and
stored at −20∘C until required for use. The remaining 1mL
was transferred into sodium fluoride containing tube for the
estimation of glucose. Fasting blood glucose (FBG), total
cholesterol (TC), triglycerides (TG), high density lipopro-
tein cholesterol (HDL) creatinine (CR), albumin (Alb), and
alanine aminotransferase (ALT) activity were analyzed using
an Erba Mannheim Chem-7 spectrophotometer (India).
2.2. Statistical Analysis. Data was entered unto a spread
sheet and analyzed using Microsoft Office Excel, 2013
(Microsoft Cooperation, Louiseville, USA), and the values
were expressed as mean plus or minus standard deviations.
The statistical Package for Social Sciences (SPSS) version
20.0 (SPSS Software, San Diego, USA) was used for most of
the statistical and analytical work with a level of statistical
significance set at𝑝 < 0.05 for all tests.Theunpaired Student’s
t-test was used to evaluate differences between two means.
Pearson product moment correlation coefficient (r) was used
to find the association between two continuous variables.
3. Results
A total of 130 subjects took part in the study with age
range of 25–83 years. The subjects were made up of 65 cases
(diabetics) comprising 28 males (43%) and 37 females (57%)
and 65 apparently healthy controls, consisting of 29 males
(44.6%) and 36 females (55.4%).The clinical and biochemical
parameters of the study population are shown in Table 1.
Diabetic subjects had significantly higher urine crea-
tinine (U-Cr), N-acetyl-𝛽-D-glucosaminidase (NAG), ala-
nine aminopeptidase (AAP), urinary albumin to urinary
creatinine ratio (U-Alb/U-Cr), NAG/U-Cr, and AAP/U-Cr
compared to controls (𝑝 < 0.05). Urinary biochemical ana-
lytes for normoalbuminuric and microalbuminuric diabetic
subjects are shown in Table 2. 9.3% and 12% of diabetics
with normoalbuminuria had elevated levels of AAP/Cr and
NAG/Cr, respectively.
Associations between correlates (eGFR, S-Cr, and dura-
tion of DM) with urinary analytes (Alb-Cr, NAG/Cr, and
AAP/Cr) were determined among type 2 diabetic subjects
and shown in Table 3.There were significant positive correla-
tions for alb/Cr, NAG/Cr, and AAP/Cr with serum creatinine
and a negative correlation between alb/Cr, NAG/Cr, and
AAP/Cr and eGFR (Table 3).
4. Discussion
Diabetic nephropathy, which is one of the microvascular
complications of diabetes mellitus, is the leading cause of
end-stage renal disease in both the developed and devel-
oping countries [11]. Microalbuminuria is the most widely
used clinical test for earliest renal involvement in diabetic
nephropathy [5]. A number of studies, however, have shown
that renal tubular lysosomal enzymes are elevated in urine
before the onset of microalbuminuria [12, 13]. This study
evaluated the urinary activities of two lysosomal enzymes
(NAG and AAP) that are located along the brush border of
the proximal tubules of the kidney.
In this study, the mean BMI of the diabetic subjects was
significantly higher than that of their nondiabetic counter-
parts (Table 1). This result was in agreement with a study
carried out in Kumasi, Ghana, by Danquah and colleagues
[14]. This could be as a result of the association of diabetes
mellitus with increased weight and obesity [14, 15].There was
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Table 1: Clinical and biochemical parameters of the study population.
Parameters Diabetics(𝑁 = 65)
Controls
(𝑁 = 65) 𝑝 value
Age (yrs) 55.3 ± 11.7 51.2 ± 11.5 0.061
SBP (mmHg) 147.8 ± 28.3 145.4 ± 21.8 0.388
DBP (mmHg) 88.8 ± 15.2 84.6 ± 10.6 0.079
BMI (kg/m2) 28.6 ± 4.7 26.2 ± 2.6 0.001
WHR (ratio) 0.88 ± 0.17 0.81 ± 0.11 0.230
FBG (mmol/L) 9.68 ± 3.4 5.8 ± 1.2 0.001
T.CHOL (mmol/L) 5.87 ± 1.1 4.88 ± 1.0 0.018
TG (mmol/L) 1.99 ± 0.7 1.60 ± 0.6 0.006
HDL (mmol/L) 1.58 ± 0.6 1.89 ± 0.7 0.006
LDL (mmol/L) 3.32 ± 0.9 2.63 ± 1.3 0.004
S-creatinine (𝜇mol/L) 98.8 ± 15.0 85.4 ± 10.9 0.001
eGFR (mL/min) 77.8 ± 10.8 93.6 ± 11.3 0.001
Period of diabetes (yrs) 8.2 ± 6.1 — —
Urinary biochemical analytes of the study population
U-creatinine (g/L) 2.1 ± 1.5 1.1 ± 0.8 0.001
U-albumin (mg/L) 46.1 ± 13.4 35.1 ± 12.8 0.092
NAG (U/L) 13.0 ± 2.2 10.1 ± 1.3 0.001
AAP (mg/L) 4.35 ± 1.3 3.89 ± 0.9 0.024
U-Alb/U-Cr (mg/g) 54.1 ± 14.9 17.8 ± 12.6 0.001
NAG/U-Cr (U/g) 17.9 ± 8.0 9.8 ± 5.4 0.001
AAP/U-Cr (ng/g) 5.74 ± 3.6 3.0 ± 2.4 0.001
Values are given as mean ± standard deviation. 𝑝 < 0.05: mean difference is significant. 𝑝 < 0.001: mean difference is highly significant. SBP is systolic blood
pressure, DBP is diastolic blood pressure, WHR is waist hip ratio, T.CHOL is total cholesterol, TG is triglyceride, HDL is high density lipoprotein, LDL is low
density lipoprotein, FBG is fasting blood glucose, BMI is bodymass index, eGFR is estimated glomerular filtration rate, NAG is N-acetyl-𝛽-D-glucosaminidase,
and AAP is alanine aminopeptidase. U-Cr is urinary creatinine and U-Alb is urinary albumin.
Table 2: Urinary biochemical analytes of microalbuminuric and normoalbuminuric diabetics.
Variable Normoalbuminuria(<30mg/g)
Microalbuminuria
(30–300mg/g) 𝑝 value
U-creatinine (g/L) 0.76 ± 0.67 1.34 ± 0.78 0.001
U-albumin (mg/L) 22.4 ± 12.1 81.56 ± 70.3 0.001
NAG (U/L) 12.88 ± 2.07 13.28 ± 2.4 0.495
AAP (ng/mL) 4.34 ± 1.26 4.35 ± 1.32 0.989
Alb/Cr (mg/g) 17.67 ± 4.86 108.7 ± 50.1 0.001
NAG/Cr (U/g) 11.83 ± 6.76 26.7 ± 17.2 0.001
AAP/Cr (ng/g) 3.84 ± 1.91 8.6 ± 5.79 0.001
% normoalbuminuric diabetics with AAP/U-Cr and NAG/U-Cr
AAP/U-Cr 9.3
NAG/U-Cr 12.0
Data is presented as mean ± SD and percentages. 𝑝 values ≤ 0.05 were considered as statistically significant. NAG is N-acetyl-𝛽-D-glucosaminidase, AAP is
alanine aminopeptidase, Cr is creatinine, Alb is albumin, and U-Cr is urinary creatinine.
no significant difference in both systolic and diastolic blood
pressures for diabetic subjects and controls. This finding
agreed with studies done elsewhere [13, 16] and could be a
result of the fact that diabetic subjects were beingmanaged on
antihypertensive medications. Subjects in the control group
were not on any form of medication. In addition, subjects
within the control group who had elevated blood pressure
did not have corresponding elevated urinary markers. This
study also revealed a significantly higher concentration of
total cholesterol (T.CHOL), LDL-cholesterol, and triglyceride
in the diabetic group compared to controls.
HDL-cholesterol was, however, significantly higher in
controls than diabetics. This lipid pattern agrees with earlier
studies [17]. This is likely the result of the association of
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Table 3: Association of urinary analytes with creatinine, eGFR, and
duration of diabetes.
Variable eGFR S-creatinine
Duration
of DM Alb/Cr
Alb/Cr (mg/g)
𝑟 =
−0.302
𝑝 = 0.014
𝑟 = 0.25
𝑝 = 0.04
𝑟 = 0.062
𝑝 = 0.604
—
—
NAG/Cr (U/g)
𝑟 =
−0.432
𝑝 = 0.001
𝑟 = 0.441
𝑝 = 0.001
𝑟 = 0.015
𝑝 = 0.907
𝑟 = 0.49
𝑝 = 0.001
AAP/Cr (ng/g)
𝑟 =
−0.352
𝑝 = 0.004
𝑟 = 0.303
𝑝 = 0.014
𝑟 = 0.065
𝑝 = 0.606
𝑟 = 0.43
𝑝 = 0.001
𝑝 values < 0.05 were considered statistically significant. Correlation coeffi-
cient 𝑟 > 0.5 shows strong positive correlation, and 𝑟 < 0.5 shows weak
positive correlation. NAG is N-acetyl-𝛽-D-glucosaminidase, AAP is alanine
aminopeptidase, Cr is creatinine, Alb is albumin, and eGFR is estimated
glomerular filtration rate.
diabetes mellitus with increased dyslipidemia. Serum crea-
tinine and estimated glomerular filtration rate (eGFR) were
significantly higher and lower, respectively, in the type 2 dia-
betic subjects than their control counterparts. These results
were in agreement with previous studies [9, 14, 16, 18].
The prevalence of microalbuminuria among the diabetics
in this study was 40% and was similar to previous studies
[14, 19]. Other studies in Tanzania [20] and Nigeria [21] had
29% and 52% prevalence, respectively. This variation could
be attributed to factors such as sample size and ethnicity.
Results from this study showed a significant increase in both
urinary NAG activity and NAG/Cr in diabetics compared
with controls. These corroborate work done elsewhere [13,
22, 23]. This study also found significant elevations in both
urinary AAP activity and AAP/Cr in the diabetics compared
with controls.The results agreed with studies done elsewhere
[24–27]. Tubulointerstitial injuries of the kidney due to devel-
opment of diabetic nephropathy in the diabetics might have
caused the elevatedNAGandNAG/Cr levels. Also, therewere
significant increases in NAG/Cr, AAP/Cr, and Alb/Cr in the
diabetics with microalbuminuria compared with diabetics
with normoalbuminuria (Table 2). This was in agreement
with work done by Nikolov and friends [9]. This could be
the result of increased tubular and glomerular lesions that
led to leakage of the enzymes into urine due to persistent
hyperglycemia in the microalbuminuric diabetics compared
to the normoalbuminuric diabetics. This study also showed
an association between correlates (eGFR, S-Cr, and duration
of DM) and urinary parameters NAG/Cr, AAP/Cr, and
Alb/Cr (Table 3). Findings are consistent with earlier research
[22]. NAG/Cr would be a preferred marker for diagnosing
diabetic nephropathy compared with AAP/Cr because it was
much more elevated in diabetics compared with controls
and also in terms of percentages among normoalbuminuric
diabetics, NAG/Cr was higher than AAP/Cr. The presence
of these elevated enzymes in normoalbuminuric patients
is an indication of tubular destruction before the onset of
microalbuminuria. Logistic and time constraints restricted
this study to the selection of type 2 diabetic subjects only.
In addition to the inclusion of type 1 diabetic subjects, we
recommend a longitudinal study to investigate the clinical
utility of NAG andAAP as a screening tool for early detection
of diabetic complications.
5. Conclusion
Results from this study showed significantly elevated levels
of urinary NAG, AAP, and albumin-creatinine ratio in the
diabetic subjects as compared to their nondiabetic counter-
parts. Furthermore, there was a strong positive correlation
of urinary enzyme activities with urinary albumin-creatinine
ratio. Urinary activities of NAG and AAP together with
their creatinine ratios could be used as markers of diabetic
nephropathy.
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